2004 related articles for article (PubMed ID: 21929649)
1. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
2. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
3. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
4. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.
Legry V; Van Rooyen DM; Lambert B; Sempoux C; Poekes L; Español-Suñer R; Molendi-Coste O; Horsmans Y; Farrell GC; Leclercq IA
Clin Sci (Lond); 2014 Oct; 127(7):507-18. PubMed ID: 24766485
[TBL] [Abstract][Full Text] [Related]
12. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.
Arsov T; Larter CZ; Nolan CJ; Petrovsky N; Goodnow CC; Teoh NC; Yeh MM; Farrell GC
Biochem Biophys Res Commun; 2006 Apr; 342(4):1152-9. PubMed ID: 16516152
[TBL] [Abstract][Full Text] [Related]
13. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice.
Ide T; Tsunoda M; Mochizuki T; Murakami K
Med Sci Monit; 2004 Oct; 10(10):BR388-95. PubMed ID: 15448592
[TBL] [Abstract][Full Text] [Related]
15. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
16. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
17. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator.
Yu J; Ip E; Dela Peña A; Hou JY; Sesha J; Pera N; Hall P; Kirsch R; Leclercq I; Farrell GC
Hepatology; 2006 Apr; 43(4):826-36. PubMed ID: 16557554
[TBL] [Abstract][Full Text] [Related]
18. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
Teoh NC; Williams J; Hartley J; Yu J; McCuskey RS; Farrell GC
Hepatology; 2010 Mar; 51(3):996-1006. PubMed ID: 20131406
[TBL] [Abstract][Full Text] [Related]
19. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
[TBL] [Abstract][Full Text] [Related]
20. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
Salamone F; Galvano F; Cappello F; Mangiameli A; Barbagallo I; Li Volti G
Transl Res; 2012 Jun; 159(6):477-86. PubMed ID: 22633099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
